DEVELOPING STORY, updated 30 October, 2023: In August 2021, the biotechnology company Cassava Sciences — makers of simufilam, an experimental Alzheimer drug currently in…
Early data presented by Cassava Sciences demonstrates the safety of their Alzheimer’s drug simufilam, which is currently in Phase 3 clinical trials. But in late…
The biotechnology company Cassava Sciences — makers of simufilam, an anti-Alzheimer’s drug currently in Phase III clinical trials — was accused of scientific misconduct…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
Scientists are diversifying their approaches to finding an effective treatment for Alzheimer’s as clinical trials targeting beta-amyloid plaques, one of the hallmarks of the…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…